<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294382</url>
  </required_header>
  <id_info>
    <org_study_id>9hospital</org_study_id>
    <nct_id>NCT03294382</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin to Improve Results in Epicanthoplasty</brief_title>
  <official_title>Botulinum Toxin to Improve Results in Epicanthoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medial epicanthal fold is a common skin fold in the inner part of the eye in more than 50%
      Asia population, giving the illusion of a shorter palpebral fissure length and a wider
      intercanthal distance. Currently, various epicanthoplasty techniques have been well described
      to correct epicanthus fold. However, hypertrophic scarring after epicanthoplasty remains a
      clinical challenge, which seems inevitable and may leading to unpleasing supratarsal crease,
      recurrence of medial epicanthus fold, even obvious scar formation. Botulinum toxin type A
      (BTX-A) is widely used for facial rejuvenation and many other medical indications. It is a
      potent neurotoxin that indirectly blocks neuromuscular transmission and leads to functional
      denervation of striated muscle for 2 to 6 months after injection. Recently, experimental
      study and clinical trails have revealed that BTX-A can inhibit the growth of fibroblasts
      derived from hypertrophic scars and influenced the expression of transforming growth
      factor-Î²1. Therefore, we hypothesized that BTX-A can improve hypertrophic scarring after
      epicanthoplasty through release orbicularis oculi muscle tension, inhibit fibroblast growth,
      and reduce collagen production. The main aim of this trail is to evaluate the efficiency of
      BTX-A injection on improving hypertrophic scaring after epicanthoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vancouver Scar scale</measure>
    <time_frame>6 month</time_frame>
    <description>Vancouver scar scale measures pigmentation, vascularity, pliability and scar height on the postoperative 6 month F/U</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intercanthal distance ratio</measure>
    <time_frame>6 month</time_frame>
    <description>the ratio of the intercanthal distance to the interpupillary distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photographic measurement</measure>
    <time_frame>6 month</time_frame>
    <description>The scar width of the patient's picture at 6 month after surgery will be measured using photoshop CS3 extended. One ruler will be placed on the patient's nose before taken the photo. Then the scar width could be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Scar</condition>
  <condition>Intercanthal Distance Ratio</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1 mL normal saline, administered in the other intercanthus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection</description>
    <arm_group_label>Botulinum toxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with moderate to severe congenital epicanthus.

          -  patients accept Park Z epicanthoplasty.

          -  Written informed consent given

        Exclusion Criteria:

          -  epicanthus caused by trauma, surgical injury.

          -  patients with both epicanthus and blepharopotosis.

          -  patients with blepharophimosis-ptosis-epicanthus inversus syndrome, or only inversus
             epicanthus

          -  patients underwent Botulinum Toxin Type A periocular injection within 6 months

          -  patients ever have been allergic to Botulinum Toxin Type A or any components of
             Botulinum Toxin Type A
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ru-Lin Huang</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ru-Lin Huang, Ph.D., M.D.</last_name>
      <phone>86-15821950669</phone>
      <email>hrl222@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chia-Kang Ho, M.D.</last_name>
      <phone>86-13817381588</phone>
      <email>610542307@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Zan, Ph.D., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ru-Lin Huang, Ph.D., M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS One. 2014 Dec 26;9(12):e115690. doi: 10.1371/journal.pone.0115690. eCollection 2014.</citation>
    <PMID>25541942</PMID>
  </reference>
  <reference>
    <citation>Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg. 2014 Sep;134(3):511-6. doi: 10.1097/PRS.0000000000000416.</citation>
    <PMID>25158709</PMID>
  </reference>
  <reference>
    <citation>Al-Qattan MM, Al-Shanawani BN, Alshomer F. Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med. 2013 Sep-Oct;33(5):482-8. doi: 10.5144/0256-4947.2013.482. Review.</citation>
    <PMID>24188943</PMID>
  </reference>
  <reference>
    <citation>Zelken J, Yang SY, Chang CS, Chang CJ, Yang JY, Chuang SS, Chen HC, Hsiao YC. Donor Site Aesthetic Enhancement With Preoperative Botulinum Toxin in Forehead Flap Nasal Reconstruction. Ann Plast Surg. 2016 Nov;77(5):535-538. doi: 10.1097/SAP.0000000000000625.</citation>
    <PMID>26418784</PMID>
  </reference>
  <reference>
    <citation>Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014 Sep-Oct;22(5):605-12. doi: 10.1111/wrr.12204. Epub 2014 Aug 26.</citation>
    <PMID>24898579</PMID>
  </reference>
  <results_reference>
    <citation>Kwon B, Nguyen AH. Reconsideration of the Epicanthus: Evolution of the Eyelid and the Devolutional Concept of Asian Blepharoplasty. Semin Plast Surg. 2015 Aug;29(3):171-83. doi: 10.1055/s-0035-1556849.</citation>
    <PMID>26306084</PMID>
  </results_reference>
  <results_reference>
    <citation>Elhefnawy AM. Assessment of intralesional injection of botulinum toxin type A injection for hypertrophic scars. Indian J Dermatol Venereol Leprol. 2016 May-Jun;82(3):279-83. doi: 10.4103/0378-6323.173586.</citation>
    <PMID>27088929</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015 Jun;14(2):161-6. doi: 10.1111/jocd.12134. Epub 2015 Mar 24.</citation>
    <PMID>25810045</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with Botulinum Toxin Type A: the Belfast experience. J Plast Reconstr Aesthet Surg. 2013 Mar;66(3):439-40. doi: 10.1016/j.bjps.2012.08.042. Epub 2012 Oct 23.</citation>
    <PMID>23092904</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang DZ, Liu XY, Xiao WL, Xu YX. Botulinum Toxin Type A and the Prevention of Hypertrophic Scars on the Maxillofacial Area and Neck: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 Mar 17;11(3):e0151627. doi: 10.1371/journal.pone.0151627. eCollection 2016.</citation>
    <PMID>26985661</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ru-Lin Huang</investigator_full_name>
    <investigator_title>Ph.D., M.D.</investigator_title>
  </responsible_party>
  <keyword>epicanthoplasty</keyword>
  <keyword>Botulinum Toxins</keyword>
  <keyword>scar</keyword>
  <keyword>intercanthal distance</keyword>
  <keyword>blepharoplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 23, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 25, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 29, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

